775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE StudyBruce E. Sands, William J. Sandborn, Peter M. Irving et al.|Gastroenterology|2021Cited by 30
Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.Роберто Пили, Noah M. Hahn, Theodore F. Logan et al.|Journal of Clinical Oncology|2019Cited by 21